{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:55:22Z","timestamp":1788432922159,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T00:00:00Z","timestamp":1540252800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Cardiovasc Drugs"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s40256-018-0305-0","type":"journal-article","created":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T04:30:20Z","timestamp":1540269020000},"page":"173-183","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Morphine and Ticagrelor Interaction in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction: ATLANTIC-Morphine"],"prefix":"10.1007","volume":"19","author":[{"name":"for the ATLANTIC Investigators","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Lapostolle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoud W.","family":"van\u2019t Hof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian W.","family":"Hamm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Stibbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Ecollan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Collet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanne","family":"Silvain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens Flensted","family":"Lassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim M. J. M.","family":"Heutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Bolognese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Warren J.","family":"Cantor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Cequier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Chettibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun G.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Hammett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Janzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9la","family":"Merkely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jur","family":"ten Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Zeymer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muriel","family":"Licour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Tsatsaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Montalescot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,23]]},"reference":[{"key":"305_CR1","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","volume":"371","author":"G Montalescot","year":"2014","unstructured":"Montalescot G, vant Hof AW, Lapostolle F, Silvain J, Lassen JF, Bolognese L, et al. Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med. 2014;371:1016\u201327.","journal-title":"N Engl J Med"},{"key":"305_CR2","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.ahj.2005.02.010","volume":"149","author":"TJ Meine","year":"2005","unstructured":"Meine TJ, Roe MT, Chen AY, Patel MR, Washam JB, Ohman EM, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE quality improvement initiative. Am Heart J. 2005;149:1043\u20139.","journal-title":"Am Heart J"},{"issue":"2007","key":"305_CR3","first-page":"e148","volume":"116","author":"JL Anderson","year":"2007","unstructured":"Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE Jr, et al. ACC, AHA, 2077 guidelines for the management of patients with unstable angina\/non ST-elevation myocardial infarction: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 2002 guidelines for the management of patients with unstable angina\/non ST-elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116(2007):e148\u2013304.","journal-title":"Circulation"},{"key":"305_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/00005344-200211000-00012","volume":"40","author":"JR Sheu","year":"2002","unstructured":"Sheu JR, Yeh GC, Fang CL, Lin CH, Hsiao G. Morphine-potentiated agonist-induced platelet aggregation through alpha2-adrenoceptors in human platelets. J Cardiovasc Pharmacol. 2002;40:743\u201350.","journal-title":"J Cardiovasc Pharmacol"},{"key":"305_CR5","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1007\/BF02256448","volume":"10","author":"G Hsiao","year":"2003","unstructured":"Hsiao G, Shen MY, Fang CL, Chou DS, Lin CH, Chen TF, et al. Morphine-potentiated platelet aggregation in in vitro and platelet plug formation in in vivo experiments. J Biomed Sci. 2003;10:292\u2013301.","journal-title":"J Biomed Sci"},{"key":"305_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ahj.2012.12.015","volume":"165","author":"G Montalescot","year":"2013","unstructured":"Montalescot G, Lassen JF, Hamm CW, Lapostolle F, Silvain J, ten Berg JM, et al. Ambulance or in-catheterization laboratory administration of ticagrelor for primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: rationale and design of the randomized, double-blind Administration of Ticagrelor in the cath Lab or in the Ambulance for New ST elevation myocardial Infarction to open the Coronary artery (ATLANTIC) study. Am Heart J. 2013;165:515\u201322.","journal-title":"Am Heart J"},{"key":"305_CR7","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1093\/eurheartj\/ehs289","volume":"33","author":"PG Steg","year":"2012","unstructured":"Steg PG, James SK, Atar D, Badano LP, Blomstrom-Lundqvist C, Borger MA, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2012;33:2569\u2013619.","journal-title":"Eur Heart J"},{"key":"305_CR8","doi-asserted-by":"publisher","first-page":"e5","DOI":"10.1016\/j.ahj.2016.07.008","volume":"180","author":"X Ruan","year":"2016","unstructured":"Ruan X, Chiravuri S, Kaye AD. The narrative review on morphine in acute coronary syndrome: recognizing opioidergic cardioprotection. Am Heart J. 2016;180:e5\u20136.","journal-title":"Am Heart J"},{"key":"305_CR9","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.ahj.2016.07.009","volume":"180","author":"CP McCarthy","year":"2016","unstructured":"McCarthy CP, McEvoy JW. The narrative review on morphine in acute coronary syndrome: recognizing opioidergic cardioprotection\u2013reply. Am Heart J. 2016;180:e7\u20138.","journal-title":"Am Heart J"},{"key":"305_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1161\/01.CIR.64.1.53","volume":"64","author":"JJ Rouby","year":"1981","unstructured":"Rouby JJ, Eurin B, Glaser P, Guillosson JJ, Nafziger J, Guesde R, et al. Hemodynamic and metabolic effects of morphine in the critically ill. Circulation. 1981;64:53\u20139.","journal-title":"Circulation"},{"key":"305_CR11","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00392-015-0835-2","volume":"104","author":"S Waha de","year":"2015","unstructured":"de Waha S, Eitel I, Desch S, Fuernau G, Lurz P, Urban D, et al. Intravenous morphine administration and reperfusion success in ST-elevation myocardial infarction: insights from cardiac magnetic resonance imaging. Clin Res Cardiol. 2015;104:727\u201334.","journal-title":"Clin Res Cardiol"},{"key":"305_CR12","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1378\/chest.125.4.1492","volume":"125","author":"JN Nanas","year":"2004","unstructured":"Nanas JN, Tsolakis E, Terrovitis JV, Eleftheriou A, Drakos SG, Dalianis A, et al. Moderate systemic hypotension during reperfusion reduces the coronary blood flow and increases the size of myocardial infarction in pigs. Chest. 2004;125:1492\u20139.","journal-title":"Chest"},{"key":"305_CR13","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.jacc.2013.10.068","volume":"63","author":"EL Hobl","year":"2014","unstructured":"Hobl EL, Stimpfl T, Ebner J, Schoergenhofer C, Derhaschnig U, Sunder-Plassmann R, et al. Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2014;63:630\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"305_CR14","doi-asserted-by":"publisher","first-page":"e001593","DOI":"10.1161\/CIRCINTERVENTIONS.114.001593","volume":"8","author":"G Parodi","year":"2015","unstructured":"Parodi G, Bellandi B, Xanthopoulou I, Capranzano P, Capodanno D, Valenti R, et al. Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention. Circ Cardiovasc Interv. 2015;8:e001593.","journal-title":"Circ Cardiovasc Interv"},{"key":"305_CR15","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","volume":"37","author":"J Kubica","year":"2016","unstructured":"Kubica J, Adamski P, Ostrowska M, Sikora J, Kubica JM, Sroka WD, et al. Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. Eur Heart J. 2016;37:245\u201352.","journal-title":"Eur Heart J"},{"key":"305_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jacc.2014.08.056","volume":"65","author":"G Parodi","year":"2015","unstructured":"Parodi G, Xanthopoulou I, Bellandi B, Gkizas V, Valenti R, Karanikas S, et al. Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study. J Am Coll Cardiol. 2015;65:511\u20132.","journal-title":"J Am Coll Cardiol"},{"key":"305_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/eci.12550","volume":"46","author":"EL Hobl","year":"2016","unstructured":"Hobl EL, Reiter B, Schoergenhofer C, Schwameis M, Derhaschnig U, Kubica J, et al. Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers. Eur J Clin Invest. 2016;46:7\u201314.","journal-title":"Eur J Clin Invest"},{"key":"305_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s00392-015-0927-z","volume":"105","author":"EL Hobl","year":"2016","unstructured":"Hobl EL, Reiter B, Schoergenhofer C, Schwameis M, Derhaschnig U, Lang IM, et al. Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers. Clin Res Cardiol. 2016;105:349\u201355.","journal-title":"Clin Res Cardiol"},{"key":"305_CR19","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1160\/TH16-02-0102","volume":"116","author":"MR Thomas","year":"2016","unstructured":"Thomas MR, Morton AC, Hossain R, Chen B, Luo L, Shahari NN, et al. Morphine delays the onset of action of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thromb Haemost. 2016;116:96\u2013102.","journal-title":"Thromb Haemost"},{"key":"305_CR20","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/eurheartj\/ehv567","volume":"37","author":"E Puymirat","year":"2016","unstructured":"Puymirat E, Lamhaut L, Bonnet N, Aissaoui N, Henry P, Cayla G, et al. Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme. Eur Heart J. 2016;37:1063\u201371.","journal-title":"Eur Heart J"},{"key":"305_CR21","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1016\/j.jacc.2013.01.024","volume":"61","author":"G Parodi","year":"2013","unstructured":"Parodi G, Valenti R, Bellandi B, Migliorini A, Marcucci R, Comito V, et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol. 2013;61:1601\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"305_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0950-3528(88)90024-3","volume":"2","author":"L Bueno","year":"1988","unstructured":"Bueno L, Fioramonti J. Action of opiates on gastrointestinal function. Baillieres Clin Gastroenterol. 1988;2:123\u201339.","journal-title":"Baillieres Clin Gastroenterol"},{"key":"305_CR23","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1160\/TH15-12-0944","volume":"116","author":"J Silvain","year":"2016","unstructured":"Silvain J, Storey RF, Cayla G, Esteve JB, Dillinger JG, Rousseau H, et al. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction: the PRIVATE-ATLANTIC study. Thromb Haemost. 2016;116:369\u201378.","journal-title":"Thromb Haemost"},{"issue":"3","key":"305_CR24","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40262-015-0320-0","volume":"55","author":"D Alexopoulos","year":"2016","unstructured":"Alexopoulos D, Barampoutis N, Gkizas V, Vogiatzi C, Tsigkas G, Koutsogiannis N, Davlouros P, Hahalis G, Nylander S, Parodi G, Xanthopoulou I. Crushed versus integral tablets of ticagrelor in ST-segment elevation myocardial infarction patients: a randomized pharmacokinetic\/pharmacodynamic study. Clin Pharmacokinet. 2016;55(3):359\u201367. \n                    https:\/\/doi.org\/10.1007\/s40262-015-0320-0\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"305_CR25","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1055\/s-0038-1629896","volume":"118","author":"M Farag","year":"2018","unstructured":"Farag M, Spinthakis N, Srinivasan M, Sullivan K, Wellsted D, Gorog DA. Morphine analgesia Pre-PPCI is associated with prothrombotic state, reduced spontaneous reperfusion and greater infarct size. Thromb Haemost. 2018;118(3):601\u201312. \n                    https:\/\/doi.org\/10.1055\/s-0038-1629896\n                    \n                  \n                           (Epub 2018 Feb 14 PMID: 29444530).","journal-title":"Thromb Haemost"},{"issue":"221","key":"305_CR26","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ijcard.2016.06.204","volume":"15","author":"B Bellandi","year":"2016","unstructured":"Bellandi B, Zocchi C, Xanthopoulou I, Scudiero F, Valenti R, Migliorini A, Antoniucci D, Marchionni N, Alexopoulos D, Parodi G. Morphine use and myocardial reperfusion in patients with acute myocardial infarction treated with primary PCI. Int J Cardiol. 2016;15(221):567\u201371. \n                    https:\/\/doi.org\/10.1016\/j.ijcard.2016.06.204\n                    \n                  \n                           (Epub 2016 Jun 29).","journal-title":"Int J Cardiol"},{"issue":"4","key":"305_CR27","doi-asserted-by":"publisher","first-page":"006833","DOI":"10.1161\/JAHA.117.006833","volume":"7","author":"M Bonin","year":"2018","unstructured":"Bonin M, Mewton N, Roubille F, Morel O, Cayla G, Angoulvant D, Elbaz M, Claeys MJ, Garcia-Dorado D, Giraud C, Rioufol G, Jossan C, Ovize M, Guerin P, CIRCUS Study Investigators. Effect and safety of morphine use in acute anterior ST-segment elevationmyocardial infarction. J Am Heart Assoc. 2018;7(4):006833. \n                    https:\/\/doi.org\/10.1161\/jaha.117.006833\n                    \n                  .","journal-title":"J Am Heart Assoc."},{"key":"305_CR28","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1111\/papr.12178","volume":"15","author":"M Galinski","year":"2015","unstructured":"Galinski M, Saget D, Ruscev M, Gonzalez G, Ameur L, Lapostolle F, et al. Chest pain in an out-of-hospital emergency setting: no relationship between pain severity and diagnosis of acute myocardial infarction. Pain Pract. 2015;15:343\u20137.","journal-title":"Pain Pract"}],"container-title":["American Journal of Cardiovascular Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-0305-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40256-018-0305-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40256-018-0305-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,25]],"date-time":"2019-10-25T15:25:02Z","timestamp":1572017102000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40256-018-0305-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,23]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["305"],"URL":"https:\/\/doi.org\/10.1007\/s40256-018-0305-0","relation":{},"ISSN":["1175-3277","1179-187X"],"issn-type":[{"value":"1175-3277","type":"print"},{"value":"1179-187X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,23]]},"assertion":[{"value":"23 October 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"This work was supported by AstraZeneca and led by the ACTION Group (Allies in Cardiovascular Trials Initiatives and Organized Networks), .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"All authors have completed the International Committee of Medical Journal Editors (ICMJE) Form for Disclosure of Potential Conflicts of Interest. Fr\u00e9d\u00e9ric Lapostolle has received research grants, consultancy fees and honoraria from AstraZeneca, Merck-Serono, Roche, Boehringer-Ingelheim, Bayer, The Medicines Company, Correvio, Daiichi-Sankyo, and Eli-Lilly. Arnoud W. van \u2018t Hof has received research grants, consultancy fees and honoraria from AstraZeneca, Medtronic, Daiichi-Sankyo, and Iroko Cardio. Christian W. Hamm has received research grants, consultancy fees, and honoraria from AstraZeneca, Daiichi-Sankyo, Lilly, Sanofi-Aventis, and Boehringer-Ingelheim. Patrick Ecollan has received consultancy fees from AstraZeneca, Abbott Vascular, Eli-Lilly, Sanofi-Aventis, and Biom\u00e9rieux. Jean-Philippe Collet has received research grants from Bristol-Myers Squibb; consulting fees from Bristol-Myers Squibb, Eli Lilly, and Sanofi-Aventis; and lecture fees from Bristol-Myers Squibb and Sanofi-Aventis. Johanne Silvain has received research grants from F\u00e9d\u00e9ration Fran\u00e7aise de Cardiologie and Soci\u00e9t\u00e9 Fran\u00e7aise de Cardiologie; consultancy fees and honoraria from Amgen, Algorythm AstraZeneca, Bayer, Gilead Science and Sanofi-Aventis; and travel support from Amgen, AstraZeneca, Bayer and Bristol-Myers Squibb. Jens Flensted Lassen has received honoraria from AstraZeneca. Leonardo Bolognese has received consultancy fees and honoraria from AstraZeneca, Daiichi-Sankyo, Eli-Lilly, Menarini Ind Farma, and Abbott. Warren J. Cantor has received honoraria from AstraZeneca. Mohamed Chettibi has received support from AstraZeneca (study investigator). Shaun G. Goodman has received support from AstraZeneca Canada (National [Canada] Coordinator) and consultancy fees and honoraria from AstraZeneca, Eli-Lilly, and Sanofi. Christopher J. Hammett has received research grants from AstraZeneca and consultancy fees and honoraria from AstraZeneca, Eli-Lilly, Bayer Healthcare, Boehringer-Ingelheim, Amgen, and The Medicines Company. Magnus Janzon has received support from AstraZeneca (National Coordinating Investigator) and Pfizer. Robert Storey has received research grants, consultancy fees and honoraria from AstraZeneca; research grants and consultancy fees from PlaqueTec; consultancy fees from Actelion\/Idorsia, Avacta, Bayer, Bristol-Myers Squibb, Pfizer, Novartis, and The Medicines Company. Jur ten Berg has received research grants, consultancy fees and honoraria from AstraZeneca. Uwe Zeymer has received research grants from Daiichi-Sankyo, Eli-Lilly, Novartis and Sanofi and consultancy fees and honoraria from AstraZeneca, Bayer Healthcare, The Medicines Company, Daiichi-Sankyo, Eli-Lilly, Novartis, Sanofi, Boehringer-Ingelheim, and Merck-Sharp and Dohme. Gilles Montalescot has received research grants (institution) from ADIR, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Celladon, Daiichi-Sankyo, Eli-Lilly, ICAN, F\u00e9d\u00e9ration Fran\u00e7aise de Cardiologie, Medtronic, Merck-Sharp and Dohme, Pfizer, Sanofi-Aventis, and The Medicines Company and consultancy fees from Amgen, AstraZeneca, Bayer, Berlin Chimie AG, Boehringer-Ingelheim, Bristol-Myers Squibb, Beth Israel Deaconess Medical, Brigham Women\u2019s Hospital, Cardiovascular Research Foundation, CME Resources, Daiichi-Sankyo, Eli-Lilly, Europa, Elsevier, Fondazione Anna Maria Sechi per il Cuore, Gilead, Janssen, Lead-Up, Menarini, Merck-Sharp and Dohme, Pfizer, Sanofi-Aventis, The Medicines Company, TIMI Study Group, and WebMD. Muriel Licour and Anne Tsatsaris are employees of AstraZeneca, while Angel Cequier, B\u00e9la Merkely, Kurt Huber, Olivier Stibbe, and Wim M.J.M. Heutz have nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}